Eli Lilly and Company $LLY Shares Bought by Ibex Wealth Advisors

Ibex Wealth Advisors grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.0% during the second quarter, HoldingsChannel reports. The firm owned 12,586 shares of the company’s stock after purchasing an additional 241 shares during the quarter. Eli Lilly and Company accounts for approximately 1.0% of Ibex Wealth Advisors’ investment portfolio, making the stock its 28th largest holding. Ibex Wealth Advisors’ holdings in Eli Lilly and Company were worth $9,811,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in LLY. Laffer Tengler Investments Inc. acquired a new position in Eli Lilly and Company in the second quarter valued at $489,000. Vise Technologies Inc. acquired a new position in shares of Eli Lilly and Company during the 2nd quarter valued at about $16,959,000. Alpha Cubed Investments LLC increased its stake in shares of Eli Lilly and Company by 6.5% during the 2nd quarter. Alpha Cubed Investments LLC now owns 14,852 shares of the company’s stock valued at $11,578,000 after acquiring an additional 912 shares during the last quarter. Allworth Financial LP lifted its holdings in shares of Eli Lilly and Company by 144.7% during the 2nd quarter. Allworth Financial LP now owns 57,329 shares of the company’s stock worth $44,690,000 after acquiring an additional 33,897 shares during the period. Finally, Cypress Capital LLC boosted its position in shares of Eli Lilly and Company by 33.2% in the second quarter. Cypress Capital LLC now owns 678 shares of the company’s stock worth $529,000 after acquiring an additional 169 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of several research analyst reports. Morgan Stanley dropped their price target on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research report on Friday, October 3rd. Daiwa Capital Markets cut shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective for the company. in a research note on Sunday, August 17th. Deutsche Bank Aktiengesellschaft dropped their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a report on Monday, August 11th. Berenberg Bank reaffirmed a “hold” rating and issued a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Finally, JPMorgan Chase & Co. reduced their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $983.76.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $923.35 on Monday. The firm has a fifty day moving average of $799.97 and a 200-day moving average of $775.01. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $955.46. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The firm has a market capitalization of $872.92 billion, a P/E ratio of 60.35, a PEG ratio of 1.21 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the previous year, the business posted $1.18 EPS. The business’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be given a $1.50 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Insider Buying and Selling

In related news, Director J Erik Fyrwald bought 1,565 shares of the stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the purchase, the director owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO David A. Ricks bought 1,632 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased 4,314 shares of company stock worth $2,766,929 over the last three months. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.